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ABSTRACT 
Adjuvants are components added to non-live vaccine formulations to enhance the effect of the 
vaccine by alerting the immune system to initiate a response against the vaccine. Powerful 
new adjuvants will be critical for the development of next generation vaccines to diseases such 
as tuberculosis, HIV-1/AIDS, malaria, and therapeutic cancer vaccines. My thesis work has 
focused on the responses induced by adjuvants targeting different immune-modulatory 
receptors in the innate immune system. The overall aim of the studies was to better 
understand the mechanisms by which adjuvants can alter innate immune activation and 
thereby influence the magnitude, polarization, and longevity of adaptive vaccine responses.  
In paper I, I investigated an adjuvant combining the toll-like receptor (TLR)3-agonist, Poly 
IC:LC, and an agonistic monoclonal antibody targeting CD40 (anti-CD40Ab) for the potential 
to induce T cell responses. We found low T cell responses in the blood, but remarkable 
frequencies of vaccine-specific T cells restricted to the lung and bronchoalveolar lavage after 
vaccination. The majority of the vaccine-specific T cells in the lung expressed CD103, 
representing tissue-resident memory T cells (TRM). However, we found that the anti-CD40Ab 
was widely disseminated after vaccination to all organs analyzed, and therefore lung-specific 
adjuvant activation alone could not explain the compartmentalized TRM.  
We consequently expanded the studies in paper II to compare the intravenous (IV) and 
subcutaneous (SQ) routes of administration. In contrast to IV, the CD40Ab stayed localized to 
the skin and the skin draining lymph nodes following SQ administration. While both groups 
induced equivalent vaccine-specific T cell homing to the lung, IV immunization induced a 
significantly higher proportion of CD103+ TRM. IV immunization induced an innate profile 
skewed towards IL-10 production, which strongly correlated with the proportion of TRM. By in 
vitro studies, we found that blood monocytes were the main producers of IL-10 and could 
mediate increased CD103 expression on T cells. IL-10 did not directly cause CD103 
upregulation, but instead conditioned monocytes to release TGFb which in turn induced the 
TRM phenotype.  
In paper III, I compared how adjuvants targeting either TLR4, TLR7/8, or TLR9 induced 
different innate immune responses to polarize the adaptive vaccine responses. In a large 
preclinical vaccine study, the TLR-adjuvants were added to polymer-based nanoparticles 
encapsulating the malaria transmission-blocking vaccine antigen Pfs25, to identify correlates 
of immunity leading to robust, long-lived, functional Ab titers. All groups induced high Ab titers 
and transmission reducing activity in mosquitoes at peak responses. However, the adjuvants 
targeting TLR7/8 or TLR9 induced higher levels of IFNα production and type I IFN associated 
gene signatures than the adjuvant targeting TLR4. The IFNα signature showed strong 
correlations with the increased Ab half-life observed in these groups. All adjuvants generated 
Pfs25-specific CD4 T cell responses when combined with the nanoparticle encapsulated 
antigen, which correlated with increased IgG Ab avidity.   
In conclusion, the thesis provides increased understanding of the mechanisms by which 
adjuvants potentiate and regulate vaccine responses and will hopefully aid in refining future 
vaccine formulations.  
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1 INTRODUCTION 
Few medical interventions have affected so many lives as vaccination.  Vaccines have the 
ability to train the immune system to fight off external pathogens or even target infected or 
cancerous cells within the body.  The immune responses generated from vaccination have 
brought several life-threatening infectious diseases under control, such as small pox, measles, 
mumps, etc.  Previous vaccination efforts have been established largely by empirical methods, 
however infectious diseases that have so far eluded standard vaccination strategies offer 
significant challenges that require a more targeted and informed approach to vaccine design.   
Most currently available vaccines work by eliciting potent antibody (Ab) responses against a 
given pathogen, but current attempts indicate that to develop vaccines against diseases such 
as HIV-1, malaria, or therapeutic cancer vaccines, Ab responses alone may not be sufficient 
to mount a protective response.  Instead, these diseases will likely need both humoral and 
cellular responses (Plotkin 2010).  As of yet, non-live vaccines have not been able to induce 
strong cellular T cell-based responses in humans, or the broad Ab responses that will likely 
be necessary for rapidly diversifying infections such as HIV-1. Therefore, a better 
understanding of how vaccine responses are induced and maintained is critical for successful 
next generation vaccines.   
As the overall goal of vaccination is to provide long-term immunological memory and 
protection, it is important to first have a deep understanding of the immune system tasked with 
providing this protection.  The immune system is broadly divided into two arms, the innate and 
the adaptive.  The innate arm provides rapid and so-called non-specific clearance or 
activation.  These effects are mediated by a multitude of cells types, including phagocytic cells, 
eosinophils, basophils, mast cells, and NK cells.  These cells jointly provide pathogen 
clearance through phagocytosis or cytolytic activity, activation of the complement system, and 
activating or educating the adaptive immune response.  In contrast, the adaptive immune 
system has developed a highly diverse and specific repertoire, capable of recognizing specific 
foreign threats and keeping a history of encountered pathogens to provide a more rapid 
secondary response.  The adaptive immune response utilizes two main components, the 
cellular and humoral, mediated by T cells and B cells, respectively.   
In this thesis, I have aimed to enhance our collective knowledge of the immunology underlying 
the initiation of a vaccine elicited response.  I will therefore provide a detailed introduction to 
the immune system, with a particular focus on the cell types evaluated throughout my work, 
namely, antigen presenting cells (APCs), T cells, and B cells.  I will then describe some of the 
major obstacles currently facing the field of vaccinology, and discuss how different aspects of 
the vaccine, such as the choice of adjuvant, vaccine formulation, and route of delivery can all 
be used in combination to overcome these obstacles.   A better understanding of the broad 
immunological response to these components of the vaccine can help tailor future efforts in 
vaccine design. 
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2 AIMS OF THESIS 
The overall aim of this thesis was to better understand the mechanisms by which immune 
stimulatory adjuvants can alter the innate immune environment and thereby influence the 
ensuing adaptive responses following vaccination.  We addressed this question by evaluating 
both innate immune activation and development of adaptive memory following immunization 
with several adjuvants that can specifically target the innate immune system.  The specific 
aims were as follows:  
 
Paper I: To study the requirements for induction of antigen-specific T cell responses with an 
adjuvant combining CD40 and toll-like receptor (TLR)3 targeting.   
 
Paper II: To determine how the innate cytokine profile contributes to the priming of tissue-
resident memory T cells (TRM) with the CD40/TLR3 adjuvant. 
 
Paper III: To compare how different TLR-ligand based adjuvants influence innate immune 
activation leading to differential long-lived Ab titers and T cell help.   
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3 IMMUNOLOGY 
3.1 INNATE IMMUNE RESPONSES 
When reacting to a natural infection, the innate immune system has the unique ability to 
respond rapidly and non-specifically by recognizing certain conserved patterns on pathogens 
known as pathogen associated molecular patterns (PAMPs).  The innate immune system can 
be divided into several different cell types, which each possess distinct combinations of pattern 
recognition receptors (PRRs), making them especially equipped to recognize and respond to 
a variety of pathogens (O’Neill et al. 2013).  Depending on which receptors are engaged, the 
cells of the innate immune system will respond accordingly in order to educate the ensuing 
adaptive responses.  Vaccines can be improved by taking advantage of this early education, 
based on a better understanding of the underlying processes of early antigen recognition and 
cellular activation.  
3.1.1 Monocyte and dendritic cell subsets 
The cells in the innate immune system are a heterogeneous population that are present in 
circulation and resident in both lymphoid and non-lymphoid tissues.  In my thesis, I focused 
primarily on APCs for their ability to elicit and instruct an adaptive response. The mononuclear 
phagocyte (MNP) system contains subsets of professional APCs and can be divided into 
monocytes, macrophages, and dendritic cells (DCs). The specific subsets have overlapping, 
but distinct functions, which will be discussed below. Although much research has focused on 
mouse MNPs in different compartments, less is known about the human counterparts. Despite 
the difficulties of studying human MNP biology, recent efforts have focused on finding 
homologies between mouse and human in terms of surface expression and immunological 
function to further understanding, and has led to a unified classification system for MNP 
subsets (Figure 1) (Guilliams et al. 2016; Haniffa et al. 2015). 
 
Figure 1: MNP subsets and function in human, rhesus macaque, and mouse. 
Of the three main arms of the mononuclear phagocyte system, DCs are particularly significant 
because of their ability to initiate and modulate naïve T cell responses. They help efficiently 
eliminate pathogens and are often considered the bridge between the innate and adaptive 
arms of the immune system.  These properties make DCs a prime target for vaccination 
efforts.  DCs were first described as Langerhans cells (LCs) in the skin in 1868. However, in 
1973 they were renamed and characterized by Ralph Steinman (Steinman & Cohn 1973, 
1974). They were ultimately identified as the innate cells that are best at educating the 
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adaptive immune response (Steinman & Witmer 1978; Nussenzweig et al. 1980).  DCs have 
now been extensively characterized, revealing several distinct cell populations. DCs are 
characterized as myeloid DCs (MDCs) or plasmacytoid DCs (PDCs).  Myeloid DCs express 
CD11c and are also known as classic or conventional DCs (cDCs). Two main subsets exist, 
cDC1, which express CD141 and CADM1 in humans or CD8/CD103 in mice, and cDC2, which 
express CD1c in humans or CD11b in mice.  While cDC1 are primarily associated with cross 
presentation of antigen to CD8 T cells, this distinction may be more pronounced in the mouse 
compared to human immune system (Segura et al. 2013).  cDC2 are classic professional 
APCs and are especially equipped to present exogenous antigen via major histocompatibility 
complex (MHC)-II to CD4 T cells.  PDCs on the other hand, are not as efficient at antigen 
presentation, but instead are highly effective in recognizing viral infections and in response 
produce high levels of type I IFNs, which can inhibit viral spread and help polarize T helper 
(TH)1 responses. 
Monocytes have classically been thought of as highly plastic cells that could differentiate into 
monocyte derived DCs or macrophages when cultured in specific cytokine milieu (Becker et 
al. 1987; Chomarat et al. 2000; Zhou & Tedder 1996) or upon entry into the tissue (Furth et 
al. 1973; Randolph et al. 1999). Therefore, tissue resident macrophage homeostasis was long 
considered dependent on continual recruitment and differentiation of monocytes. However, 
recent studies evaluating the ontogeny of MNP subsets have refined this view.  Instead, it has 
become clear in mice that tissue macrophages are actually derived during early development 
and persist throughout adulthood, with a limited need for replacement by circulating 
monocytes.  This concept was first demonstrated with microglia, the macrophages resident in 
the central nervous system.  Microglial cells were found to in fact have a distinct ontogeny 
from circulating monocytes and originated from yolk-sac derived primitive myeloid progenitors 
(Ginhoux et al. 2010).  This work has since been expanded to evaluate resident macrophages 
in multiple tissues to confirm the findings, showing that macrophages seed developing fetal 
tissues (Epelman et al. 2014; Hashimoto et al. 2013; Tamoutounour et al. 2013).  In contrast, 
circulating monocytes are continually generated in the bone marrow from hematopoietic stem 
cells. Within different tissue microenvironments, macrophages have different phenotypes and 
functions specific for the environmental niche, but overall, they are particularly potent at 
phagocytosis.  
Although macrophages have now been shown to have a distinct origin from monocytes, 
monocytes are in fact still a highly plastic population that have the capacity to differentiate into 
macrophages or DCs in the tissue when needed, in situations such as inflammation or 
infection.  Even within circulation, monocytes are highly plastic, responding to danger signals 
and inflammation.  In circulation, monocytes fall into different sub-populations, Ly6Chi and 
Ly6Clow in mice, or classical (CD14+), non-classical (CD16+), and intermediate 
(CD14+CD16+) monocytes in humans.  When using flow plots of CD14 vs CD16, human 
monocytes are often described as taking on a “waterfall” like shape, indicating a continuous 
differentiation between the subsets (Haniffa et al. 2015; Patel et al. 2017; Sugimoto et al. 
2015). Upon inflammation, classical monocytes can readily differentiate, becoming 
intermediate CD14+CD16+ cells.  To date, it is unclear whether there is a functional homolog 
to intermediate monocytes in mice.  However, classical monocytes in both humans and mice 
readily migrate to sites of inflammation in tissue and can differentiate into peripheral 
mononuclear phagocytes.  Interestingly, upon entering the tissue, monocyte derived 
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macrophages and DCs will take on many of the functional characteristics of resident 
populations.  In particular, they often upregulate molecules associated with antigen uptake 
and presentation, a requirement for a successful immune response following infection and 
inflammation (Tamoutounour et al. 2013). Ly6Clow or CD16+ non-classical monocytes 
preferentially patrol the endothelium and are less likely to enter tissue and differentiate in 
response to inflammation (Cros et al. 2010).  Recent reports have even highlighted the 
possibility of tissue monocytes, which traffic through lymphoid and non-lymphoid tissues at 
steady state without significant changes in their gene expression profiles (Jakubzick et al. 
2013). These cells were implicated in antigen trafficking from tissue to lymph nodes during 
steady state, and therefore may be important for initiation of T cell responses. 
3.1.2 Maturation and presentation 
APCs are primed to be sentinels of the immune system, due to their distribution throughout 
the body, particularly at interfaces between the body and the environment.  They are found in 
the blood, but are especially prevalent in airway epithelium, skin, and mucosal surfaces 
(Figure 2).   
 
Figure 2: APC subset distribution in skin, blood, and lymph node. 
In these vulnerable locations, the immature form of DCs can patrol for invading pathogens and 
capture antigens through several mechanisms. Like other cells of the innate immune system 
they are capable of phagocytosing microbes and particles.  Additionally, they can sample 
extracellular fluid in a process called micropinocytosis (Sallusto et al. 1995) or utilize receptor 
mediated endocytosis through a variety of receptors such as C-type lectin receptors, DEC-
205 (Jiang et al. 1995) or Fc receptors (FcR).  These processes are highly efficient in DCs 
and therefore much lower concentrations of antigen are required for antigen presentation than 
compared to other APCs (Sallusto et al. 1995).   
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As a result of antigen uptake and external signals from PRR engagement, the DCs will 
undergo a process called maturation.  During this process, the DC downregulates its capacity 
to acquire antigen, and instead shifts towards a phenotype better suited to initiate an adaptive 
immune response.   Unlike in macrophages, where antigen is shuttled largely to lysosomes to 
be completely degraded, DCs traffic proteins to endosomal structures, which contain high 
levels of MHC-II.  In these structures, DCs can degrade antigen protein into peptides and then 
assemble antigen-MHC-II complexes. The cell then re-distributes its MHC-II molecules from 
endosomes/lysosomes to the surface of the cell. Signals from TLR engagement, TNF-receptor 
family engagement (such as CD40) or cytokines from other innate cells further mature the 
DCs. DCs then upregulate co-stimulatory molecules, such as CD80/86 and CD70, critical for 
antigen presentation to T cells.   
Upon maturation, DCs alter their chemokine receptor expression and migrate out of the tissue 
to lymphoid tissues, where they can interact with T cells and B cells.  Under steady state 
conditions, DCs migrate from the periphery to lymph nodes for immune surveillance and to 
maintain peripheral T cell tolerance (Scheinecker et al. 2002).  However, under inflamed 
conditions, DCs will downregulate chemokine receptors such as CCR1 and CCR5, while 
upregulating CCR7 to facilitate enhanced DC migration to the lymph node (Johnson & Jackson 
2014).  During homeostasis, low levels of the CCR7 ligand, CCL21, are expressed, but 
inflammation leads to new production and secretion of CCL21, allowing for DC adhesion and 
transmigration (Sallusto et al. 1998).   This enhanced migration results in tissue DCs becoming 
the major subset in the lymph node (Jakubzick et al. 2008).  Upon entry to the lymph node, 
tissue DCs carrying antigen from the periphery are now poised to find their cognate T cell and 
initiate an immune response. 
Within the lymph node, professional APCs can present antigen to CD4 T cells via MHC-II, or 
by a process called cross presentation, present antigen to CD8 T cells via MHC-I. MHC-II is 
only expressed on professional APCs and presents antigens derived from the extracellular 
domain.  In contrast, MHC-I is expressed on all nucleated cells and presents endogenous 
antigen to T cells. This provides a mechanism for CD8 T cells to recognize non-self antigen 
expressed on MHC-I and kill infected cells.  However, cross presentation exists as a means 
to prime naïve CD8 T cells to pathogens that do not infect APCs.  Cross presentation occurs 
through two primary pathways, the cytosolic and the vacuolar (Joffre et al. 2012).  Through 
the cytosolic pathway, antigen is taken up extracellularly and escapes from the endosome into 
the cytosol where it is degraded by the proteasome (Kovacsovics-Bankowski & Rock 1995).  
In the vacuolar pathway, proteins are degraded in the phagosome and loaded onto MHC-I.  
Cross presentation is particularly important for protein-based vaccine development, where 
exogenous protein needs to be presented via MHC-I to prime a CD8 T cell response.  Although 
this pathway seems to be largely restricted cDC1s in mice in vivo (Joffre et al. 2012), it is 
unclear if this distinction is as definitive in humans (Albert et al. 1998b, 1998a; Segura et al. 
2013; Segura & Amigorena 2015; Tang-Huau et al. 2018).  There is evidence that cDC1s are 
superior in humans, but information is limited and primarily derived from blood cDC1s 
(Bachem et al. 2010; Crozat et al. 2010; Jongbloed et al. 2010; Mittag et al. 2011).  Further 
these studies showed that the cross-presentation capacity was increased following TLR 
stimulation. However, multiple DC subsets sorted from human tonsil showed similar 
capabilities of cross presentation at baseline (Segura et al. 2013). Therefore, it seems that the 
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pathways for cross presentation are conserved between species, but not dependent on a 
specific DC subset in humans.   
3.2 T CELL RESPONSES 
3.2.1 Generation of T cell responses 
A strong understanding of the role of DCs in polarizing TH cells can be used to enhance and 
adapt the immune response as necessary.  Naïve T cells derived from precursors in the 
thymus move to the periphery where they can interact with DCs to become activated.  DC 
priming of T cells in the lymph nodes has a large impact on the ultimate fate of the T cell, which 
is principally determined by three signals (Figure 3).   
 
Figure 3: T cell activation requires three DC-derived signals. 
The first signal is the initial contact between the DC and T cell, where the T cell receptor (TCR) 
binds to the peptide:MHC-II complex on the DC to determine the antigen specificity.  A 
complementary TCR and antigen complex is not sufficient to stimulate a naïve immune 
response however.  The second signal ensures that there is a threat associated with the 
antigen and arises from the binding of costimulatory molecules.  As DC maturation leads to 
upregulation of costimulatory molecules such as CD80/86 and CD70, there is an increased 
likelihood of binding to their receptors, CD28 and CD27 respectively.  With sufficient 
stimulation through signal 2, the T cell will become an effector cell, or will otherwise become 
anergic.  Finally, signal 3 determines the polarization of the T cell to a TH1 or TH2 cell.  The 
conditions under which a DC is primed will lead the DC to secrete certain factors that can 
influence the T cell polarization (Kapsenberg 2003).  An intracellular infection requiring cellular 
immunity will condition DCs to make more TH1 driving factors such as IL-12 (Macatonia et al. 
1995; Trinchieri 2003), IL-23, IL-27, type I IFNs (Kadowaki et al. 2000; Wenner et al. 1996), 
and ICAM1.  Instead, an extracellular pathogen, which would be more efficiently cleared by 
Ab responses, will stimulate DCs to produce more TH2 factors such as the cytokines IL-4, IL-
5, IL-9 or co-stimulatory factors such as MCP1 or Ox40L.  Additionally, DCs that produce 
cytokines such as IL-10 and TGFβ have a regulatory effect and can induce T cells to take on 
a regulatory T cell phenotype.  These factors are produced at low levels after DC maturation 
and will then increase with signal 2 engagement. However, these classifications are constantly 
evolving, and something that was evaluated throughout my thesis.    
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An additional pathway critical in the activation of naïve T cells is the CD40/CD40-ligand 
(CD40L) pathway.  CD40 is broadly expressed on APCs, including DCs, B cells, and 
monocytes, as well as non-immune cells such as platelets and epithelial cells.  CD40L is 
primarily expressed on TH cells. During the DC-T cell interaction it is important the DC has 
strong cross talk with the T cell.  T cells will upregulate CD40L after DC derived signals 1 and 
2 (Grewal & Flavell 1998; Krug et al. 2001; Schulz et al. 2000) and bind to CD40 expressed 
on DCs to maintain contact during interaction.  Further, CD40 ligation allows the TH cells to 
license the DCs and leads to increased costimulatory and MHC molecule expression (van 
Kooten & Banchereau 2000) as well as proinflammatory cytokine production, such as IL-12 
(Diehl et al. 2000). This DC licensing is critical for the generation of effective CD8 T cell 
responses and can lead to tolerance in the absence of CD40 (Buhlmann et al. 1995).  In 
addition to DCs, B cells will also increase their antigen presentation capacity and proliferate in 
response to CD40 stimulation. However, the response to CD40 stimulation varies depending 
on the cell expressing CD40 and the microenvironment (van Kooten & Banchereau 2000). 
3.2.2 Re-activation of memory T cells 
Once activated, T cells can take on a variety of functions.  Some will travel through the 
peripheral blood and continue to circulate, while other subsets will move to different tissue 
compartments, and even become resident there.  The T cell’s function is largely determined 
by imprinting from DCs during their initial education.  A major goal of vaccination is to elicit 
memory T cells without an actual threat, to protect the host during future infections.  Memory 
T cells can be recalled later during infection and have classically been categorized into two 
main subsets, effector memory (TEM) and central memory (TCM) (Sallusto et al. 1999). These 
cells can be distinguished based on their expression of the markers for lymph node homing 
and function, primarily CCR7 or CD62L and CD45RA or CD45RO (Figure 4A). TEM are more 
cytotoxic and primarily located in blood, spleen, and non-lymphoid tissue.  These cells are 
double negative for CD45RA and CCR7, with the lack of CCR7 expression explaining their 
inability to migrate to lymphoid tissue. Alternatively, long-lived TCM are more proliferative and 
are CD45RA-/CCR7+.  Through expression of lymph node homing markers such as CCR7, 
TCM survey lymphoid tissue for their cognate antigen (Figure 4A) (Sallusto et al. 2004).  
 
 
 
 
Figure 4: Memory T cell subsets in different anatomical compartments and phenotypic characterization. 
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However, recent studies evaluating the migration patterns, function, and development of 
memory T cells have challenged this dichotomous T cell lineage and revealed new subsets. It 
now seems that T cell subsets are more complex than cytotoxic TEM in peripheral tissues and 
proliferative TCM in lymphoid tissues.  For example, cytotoxic TEM are not typically found in the 
lymph node, however cells within the lymph node would need to provide cytotoxic effector 
function in case of infection by bacteria or virus within the lymphoid organ (Kastenmüller et al. 
2012) and T cells that take up residence in the tissue have proliferative capacity for self-
renewal unlike classical TEM (Beura et al. 2018; Park et al. 2018).  To clarify these distinctions, 
CX3CR1 can be used as a phenotypic marker that differentiates between memory cells with 
a cytotoxic profile (CX3CR1+) versus proliferative (CX3CR1-) (Böttcher et al. 2015; Gerlach 
et al. 2016).  Additionally, CX3CR1 can distinguish three distinct subsets of memory T cells 
with high, intermediate, or low expression (Gerlach et al. 2016).  Surprisingly, the CX3CR1int 
cells were the main subset in non-lymphoid tissues and the classical TEM (CX3CR1high) were 
found exclusively in the blood and spleen (Gerlach et al. 2016). This finding has dramatically 
altered our understanding of T cell migration patterns and development, and has even 
suggested the CX3CR1int cells be termed peripheral memory (TPM).  However, these findings 
need to be evaluated further in humans. Another revelation that argued against the role of TEM 
in peripheral tissues was the discovery of tissue-resident memory T cells (TRM). TRM are 
memory T cells resident in a multitude of tissues to provide a front line of defense and do not 
recirculate. Recent quantitative data from mice shows that following infection the majority of 
memory T cells are actually tissue-resient and not recirculating memory T cells as previously 
believed (Steinert et al. 2015). TRM can be distinguished by their expression of CD69 and/or 
CD103 (Figure 4B) and are the predominant subset in lungs, intestines, vaginal mucosa and 
skin (Figure 4C) but are also found in liver, brain and lymphoid tissues (Schenkel & Masopust 
2014; Mueller et al. 2013).  It seems that they have an even broader distribution in humans 
than mice (Thome et al. 2014), indicating a key role in protection and maintenance of 
immunological memory. 
3.2.3 Tissue-resident memory T cells 
Considering the high prevalence of TRM, it is surprising that they were not discovered and 
characterized until 2008-2010.  During this time, two groups demonstrated that T cells found 
in the skin and dorsal root-ganglia after herpes simplex virus (HSV) infections, or in the small 
intestine after lymphocytic choriomeningitis virus (LCMV) were in fact a new subset of tissue-
resident T cells (Gebhardt et al. 2009; Masopust et al. 2010; Wakim et al. 2008).  The reason 
TRM went undetected for so long may be largely due to technical obstacles. Until recent 
technological advances, there were difficulties to differentiate circulating TEM from bona fide 
resident TRM. It has since been shown that many of the TEM characterized in tissue were 
actually contaminating from the blood vasculature found in tissues (Anderson et al. 2012).  
Therefore, intravascular staining techniques were developed to specifically label cells found 
within the vasculature at time of tissue collection (Anderson et al. 2012).  It has also been 
shown that standard methods for cell isolation from whole tissues result in a poor cell yield 
and are biased towards certain cell subsets (Steinert et al. 2015).  When compared to 
quantitative microscopy, TRM have been vastly underestimated using standard methods such 
as flow cytometry, and in fact far outnumber recirculating cells in the tissue (Steinert et al. 
2015). These new methods, which include intravascular staining, tissue grafts, and parabiosis 
experiments, have now identified TRM in a wide range of tissues (Mueller & Mackay 2016).  
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Aside from their wide distribution, TRM have now been shown to be integral to secondary 
responses against infections. For example, they have been demonstrated to be critical in 
providing heterosubtypic immunity against influenza, protective T cell responses against 
respiratory syncytial virus (RSV), improved prognosis in cancer immunotherapy, and 
protection against several infections of the skin, most notably HSV (Muruganandah et al. 
2018). 
After identifying the phenotype and distribution of TRM, much effort has focused on 
understanding their development.  TRM share a common clonality with TCM, and appear to 
develop from a common precursor after entry into the tissue (Gaide et al. 2015; Mackay et al. 
2013). Environmental signals such as cytokines or local antigen persistence have been shown 
to drive TRM formation (Bergsbaken et al. 2017; Casey et al. 2012; Schenkel et al. 2016; Khan 
et al. 2016; Mackay et al. 2013, 2015; McMaster et al. 2018; Muschaweckh et al. 2016).  For 
example, following HSV infection, T cells enter the skin via chemokine gradients, particularly 
via CXCL9/CXCL10 and CXCR3, and progressively acquire a transcriptional profile that is 
distinct from TCM, which coincides with upregulation of CD69 and CD103 (Mackay et al. 2013).  
CD69 is an early activation marker, but can also be upregulated independent of antigen, and 
promotes tissue residence by inhibiting shingosine-1-P receptor (S1PR) and thereby inhibiting 
lymphocyte egress (Matloubian et al. 2004; Shiow et al. 2006).  CD69 has been shown to be 
a key marker to distinguish TRM from circulating cells in humans, and helped identify a core 
transcriptional profile across multiple donors and tissues (Kumar et al. 2017).  CD103 is 
expressed on a subset of CD8 TRM and is not expressed by CD4 TRM in humans (Kumar et al. 
2017). CD103 binds to E-cadherin, an adhesion molecule on epithelial cells, and therefore 
helps maintain residence in epithelial compartments. While CD69 is upregulated relatively 
quickly, CD103 may represent a late stage TRM and could be dependent on antigen or specific 
tissue localization (Mackay et al. 2015). Although multiple cytokines have been implicated in 
driving TRM differentiation and maintenance in the tissue, TGFb has been most definitively 
characterized for CD103 upregulation (El-Asady et al. 2005; Mackay et al. 2013, 2015; Wang 
et al. 2004).  TGFb is constitutively expressed in many epithelial compartments (Kane et al. 
1990; Koyama & Podolsky 1989) and has long been known to drive CD103 expression (Casey 
et al. 2012; El-Asady et al. 2005; Wang et al. 2004). T cell expression of TGFb receptor 2 is 
required for upregulation of CD103 and induction of TRM (Mackay et al. 2013).  Following 
upregulation of the phenotypic markers CD69 and or CD103, TRM are then maintained in the 
tissue long-term through local proliferation, particularly after secondary infection (Park et al. 
2018). 
Over time, TRM begin to lose their cytotoxic capacity, indicating their function may be primarily 
to patrol and act as an alarm system, instead of providing direct effector function (Figure 5) 
(Beura et al. 2018; Schenkel et al. 2013; Mintern et al. 2007; Muruganandah et al. 2018; Park 
et al. 2018). In line with this function, TRM have a dendritic-like quality and can travel randomly 
between keratinocytes to patrol the skin for infections (Ariotti et al. 2012). Although TRM may 
have lower cytotoxic function, they are highly proliferative and multifunctional (Pizzolla et al. 
2018).  Therefore, after encounter with their cognate antigen, the TRM slows its migration and 
loses its dendritic qualities (Ariotti et al. 2012; Gebhardt et al. 2011; Park et al. 2018).  Here, 
the TRM can proliferate and produce high levels of cytokines, such as IFNg, which can act as 
an alarm and recruit other cells of the immune system. However, it was shown that skin TRM 
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were still sufficient for protection against HSV in the absence of circulating memory T cells, 
indicating they are also capable of exerting function without recruiting circulating T cells 
(Mackay et al. 2015). The extensive recent work in mice has provided critical understandings 
of the developmental pathway and function of TRM, however it remains unclear how to best 
induce them via vaccination and how findings in mice will translate to humans.  
 
Figure 5: TRM function during the event of antigen re-exposure.  
3.3 B CELL RESPONSES 
While much of the work performed in this thesis evaluates the induction and maintenance of 
T cell memory, most vaccines available today rely on Ab-mediated protection.  Therefore, it is 
imperative to have a comprehensive understanding of the B cell biology required to generate 
protective Ab responses. Two primary cell types, memory B cells (MBCs) and long-lived 
plasma cells (LLPCs) mediate long-term Ab memory.  MBCs provide rapid recognition to an 
incoming threat, and can respond by proliferation and enhanced Ab production.  In contrast, 
LLPCs provide constant production of secreted Abs to provide a front line of defense.  
3.3.1 Generation and re-activation of B cell responses 
Naïve B cells express Abs of a single specificity on their cell membrane, which function as a 
B cell receptor (BCR).  They migrate through the peripheral blood and can enter the lymphatic 
system to sample antigen within the lymph node either captured on follicular DCs (FDCs) or 
via subcapsular macrophages (Junt et al. 2007; Phan et al. 2009; Szakal et al. 1988). Upon 
BCR engagement, antigen is internalized and presented to CD4 T cells at the B cell-T cell 
border (Lanzavecchia 1990, Van Kooten and Banchereau 2000, Okada 2005).  T cell help is 
critical for the induction of class switched and high affinity antibodies (Figure 6).   
 
 
 
Figure 6: T cell-independent and dependent Ab production. 
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Through T cell help, B cells can follow two potential pathways, which may be dictated by the 
affinity of the Ab and the strength or duration of T cell contact (Allen et al. 2007; Schwickert et 
al. 2011).  B cells will either receive signals to enter the germinal center or extrafollicular areas 
(Jacob et al. 1991; Liu et al. 1991).  B cells that maintain longer contact with T cells are more 
likely to become a germinal center B cell, whereas short contacts are more likely to enter the 
extrafollicular pathway and become short lived Ab secreting cells (Schwickert et al. 2011).  
The germinal center is a structure found within lymph nodes critical for development of mature 
B cells (Figure 7).  It is within the germinal center structure that B cells can proliferate, 
differentiate, undergo class-switching and affinity maturation through a process called somatic 
hypermutation (SHM). Mutated B cells compete for signals to determine which cells have the 
highest affinity to be selected for differentiation into plasma cells or MBCs.  As the germinal 
center matures, two compartments develop, the light zone and dark zone.  Within the dark 
zone, B cells undergo proliferation and SHM.  In the light zone, B cells interact with a 
specialized CD4 T cell, termed T follicular helper cell (TFH), and sample BCR interactions with 
antigen sequestered on FDCs. TFH secrete high levels of IL-21 to provide B cell help and act 
as a gatekeeper for B cells following SHM.  Only B cells with the highest affinity for the antigen 
that can present to cognate TFH will receive signals to stay alive.  B cell migration between the 
two zones is an iterative process, where B cells undergo multiple rounds of mutation and 
competition for survival (Allen et al. 2007; Gitlin et al. 2014; Schwickert et al. 2007; Victora et 
al. 2010).  Cells that do not have appropriately high affinity or have acquired autoreactivity die 
by apoptosis. Thus, out of the germinal center comes a diverse repertoire of B cells with high 
affinity antibodies.  These B cells can be Ab secreting cells, either short-lived plasmablasts or 
long-lived plasma cells; or memory B cells.  Upon secondary encounter, memory B cells can 
proliferate in response to BCR binding without the need for cognate CD4 T cell help. It is critical 
to induce both of these cell types for an effective vaccine, as plasma cells can constitutively 
produce protective Abs, but memory B cells can be rapidly reactivated, producing higher levels 
of Abs and restarting the germinal center reaction after booster vaccinations or natural 
infections.   
 
Figure 7: The germinal center reaction within a B cell follicle of a lymph node.  
3.3.2 Antibody responses 
Several models have been proposed for the maintenance of Ab titers over time (Amanna & 
Slifka 2010).  However, more work evaluating the kinetics and maintenance of B cell 
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populations in combination with detailed measurements of Ab responses is required to fully 
delineate a working model.  Currently, there are two primary categories of models, based on 
MBC replenishment or the lifespan of plasma cells (Amanna & Slifka 2010).  Immunological 
memory based on MBCs could be maintained through several possible mechanisms, as 
illustrated below (Figure 8A). A seminal paper evaluating Ab titers and half-life against a variety 
of antigens in 45 volunteers over a period of almost three decades can be used to assess 
these models and to better understand maintenance of Ab titers (Amanna et al. 2007).  
Through chronic infection and repeated antigen exposure, Ab titers could stay elevated over 
the course of a lifetime, however this only represents a minority of infections (Figure 8A, black).  
Further, the half-life of two chronic infections, Epstein-Barr virus (EBV) and varicella zoster 
virus (VZV), differ dramatically (Amanna et al. 2007).  While EBV generates very stable Ab 
titers, with a half-life of almost 12,000 years, titers against VZV decline over time and have a 
half-life of approximately 50 years.    These responses are more short-lived than several acute 
infections, indicating that chronic infection or cross-reactivity of B cell clones should not be the 
major source of immunological memory.  Additionally, if MBCs required persistent antigen, 
you would expect Ab titers to drop off after the clearance of antigen (Figure 8A, green). It has 
been demonstrated that small amounts of antigen can be retained on FDCs with a half-life of 
approximately 8 weeks (Tew & Mandel 1979).  You would therefore expect Ab titers to follow 
a similar half-life, however both natural infection and vaccination have shown significantly 
longer half-lives.  Polyclonal activation through means such as TLR stimulation or cytokine 
stimulation would generate random blips of Ab production overtime (Figure 8A, blue).  In vitro, 
MBCs can respond to TLR and cytokine stimulation to differentiate into Ab secreting cells 
(Bernasconi et al. 2002), however Ab titers against irrelevant antigens would then increase in 
coordination with most immunizations or infection.   
 
Figure 8: Models for Ab titer maintenance and B cell populations involved. 
Finally, repeated infection or vaccination can lead to specific increases in Ab production that 
coincide with reinfection or immunization, that gradually decrease overtime until the next re-
exposure (Figure 8A, purple) (Amanna et al. 2007; Genova et al. 2006).  The peak in Ab titers 
appears after bursts of plasmablasts, or short-lived plasma cells that are derived from MBC 
restimulation and expansion (Figure 8B).  While the MBC populations also expand and 
contract with repeated infections, the numbers of LLPCs appear to be established early after 
infection or vaccination and the numbers appear to remain relatively stable overtime (Lindgren 
et al. 2017; Sundling et al. 2013).  While this pattern describes many vaccinations, 
immunizations against measles, mumps, and rubella have all generated long Ab half-lives, 
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ranging from 100-3000 years, and the titers can be maintained for decades without local 
outbreaks or exposure.  Therefore, a fundamental question in vaccinology is how to imprint 
these types of long-lived responses using non-live vaccines without the need for continual 
boosting. 
Two models have additionally been proposed for plasma cell-based Ab maintenance, which 
would not require replenishment by MBC.  Although MBCs would still be critical for rapidly 
responding to reinfection, this model is theoretically possible since it has been demonstrated 
that LLPCs and Ab titers can be maintained overtime, even if MBCs have been depleted 
(Ahuja et al. 2008; DiLillo et al. 2008; Slifka et al. 1998).  Differences in Ab half-lifes indicate 
that LLPCs also have different lifespans.  One possible explanation is the plasma niche theory, 
which proposes that plasma cells compete for limited space in survival niches such as the 
bone marrow (Figure 8A, orange) (Radbruch et al. 2006).  Once a LLPC is displaced from the 
survival niche it would die, making room for new LLPCs.  However, this would predict that 
following each immunization there would be less space for previous LLPCs and there would 
consequently be a reduction of Ab titers against irrelevant antigens. Further, competition within 
the bone marrow would increase with age, indicating the Ab titers would decrease at a faster 
rate later in age.  However, neither of these phenomena have been seen in an appreciable 
way (Amanna et al. 2007). Therefore, while there may be competition within the bone marrow, 
it is unlikely that this is the primary cause of differences in lifespan.  Instead, it seems likely 
that when plasma cells are induced they are initially imprinted with a specific lifespan (Figure 
8A, red). This model accounts for differences in T cell help during initial priming and the 
strength of BCR signaling or crosslinking, which could together imprint a specific lifespan of 
the LLPC.  It would therefore be critical to initiate a strong germinal center response to initiate 
LLPCs capable of lasting decades after immunization.  The proposed imprinted lifespan theory 
follows a biphasic model (Figure 8B).  After an initial increase following immunization or 
infection, there is a rapid reduction in the Ab titers dictated by the Ab half-life, which is 
approximately 20 days.  Following this rapid decline, the second phase is dictated first by 
short-lived plasma cells and possibly antigen retention, and finally Ab titers are maintained by 
LLPCs (Amanna & Slifka 2010).  Together this model suggests that we need a much better 
understanding of the initiation of B cell responses within the germinal center response, to 
understand how to design vaccines to elicit LLPCs with an increased imprinted lifespan. 
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4 VACCINATION 
Vaccines have been fundamental in efforts to alleviate human morbidity and mortality.  Since 
the first recorded use of vaccination in 1796 by Edward Jenner to protect against smallpox, 
vaccines have been developed against an outstanding array of diseases and have been able 
to control or even eliminate many of them.  However, today there are still significant challenges 
ahead for future vaccination efforts.  Traditionally, vaccines have been developed using 
empirical methods and followed a standard protocol of isolate, inactivate, and inject (Figure 9) 
(Rappuoli 2000; Rappuoli et al. 2016).  Today, a convergence of a variety of fields including 
genetics, immunology, structural biology, and computational biology have allowed for a new 
approach to vaccine development and design, termed “reverse vaccinology” (Rappuoli 2000; 
Rappuoli et al. 2016).  This process does not rely on culturing the pathogen for inactivation, 
but instead starts with the genetic or structural sequences to identify potential vaccine 
candidates and antigens.  Using this approach, a great deal of vaccine design is now required 
to elicit the optimal response.  
Multiple components of the 
vaccine can be altered and 
must now be considered 
when developing a new 
candidate, including antigen, 
adjuvant, formulation, and 
route of delivery (Figure 9).  
Together, a better 
understanding of all these 
components of a vaccine can 
help overcome the current 
challenges of vaccines, and 
will be discussed below.  
Figure 9: Requirements for conventional and contemporary vaccine design. 
4.1 VACCINES FOR UNMET NEEDS 
4.1.1 T cell-based vaccines 
As discussed above, vaccines against HIV, tuberculosis (TB), malaria, and cancer 
immunotherapies will likely require induction of CD8 T cell responses.  However, most 
vaccines to date rely on Ab mediated protection and it has been difficult to generate effective 
CD8 responses, in particular to sub-unit vaccines.  Although viral vectored vaccines, such as 
those based on adenovirus (Ad) vectors have been able to generate strong CD8 T cell 
responses, setbacks such as failures of Ad5-based HIV-1 vaccine trials have slowed their 
clinical implementation. The STEP trial, one of the early HIV-1 large-scale efficacy trials based 
on Ad-5, was prematurely halted due to increased infection susceptibility in men with a high 
seroprevalence of Ad5 (Buchbinder et al. 2008).  However, there is still motivation to generate 
an HIV vaccine that induces CD8 T cell responses, ideally in combination with potent Ab 
responses.  The gold standard for an HIV vaccine has long been to establish broadly 
neutralizing antibodies (bNAbs), or antibodies that can neutralize multiple strains across 
different clades.  However, bNAbs only develop in a small subset of HIV-infected individuals 
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and have proven to be exceedingly difficult to elicit via vaccination efforts.  These Abs often 
take years of chronic infection to develop and have several unique properties, making them 
particularly difficult to develop (Geiß & Dietrich 2015).  However, CD8 T cells, known to control 
HIV replication early after infection, may limit the viral reservoir and have been shown to be 
associated with disease non-progression (Boaz et al. 2002; Hess et al. 2004; Migueles et al. 
2002; Streeck et al. 2008).  Recent studies have identified a vaccine strategy that protects 
rhesus macaques from SIV infection mediated by CD8 T cells (Hansen et al. 2009, 2011, 
2013).  This strategy uses a cytomegalovirus (CMV) vector and elicits a TEM response that is 
HLA-E restricted, and will soon be tested in clinical trials.  The HIV/AIDS epidemic has also 
made clear the role for T cell responses in protection against TB.  HIV makes patients highly 
susceptible to infection and reactivation of latent TB due to the decrease in CD4 T cells.  It 
also seems that CD8 T cells are critical in protection against TB, although this has not been 
as thoroughly explored (Lin & Flynn 2015).  CD8 T cells also likely play a role in heterosubtypic 
protection against influenza (Slütter et al. 2013, 2017; Zens et al. 2016), and could hold the 
key to avoiding yearly vaccination efforts presently needed.  Finally, it is clear that T cell 
responses will be necessary for successful therapeutic cancer vaccines.  The recent 
blockbuster success of checkpoint blockade therapies targeting PD-1 and CTLA-4 have 
demonstrated the potential to unlock T cell responses.  Further, the advent of CAR-T cells and 
adoptive cell therapy have further emphasized the role of T cell mediated effect.  However, 
work is still needed to design vaccines that can elicit de novo T cell responses to provide 
therapeutic effect.   
4.1.2 Malaria vaccines 
Malaria is another disease that causes a substantial global public health burden, but has so 
far eluded standard vaccination strategies.  Several factors have complicated the development 
of a vaccine to malaria, including the complex life cycle of the Plasmodium parasite, large 
antigenic variation, and an overall poor understanding of the interactions between the parasite 
and human immune system. Candidate vaccines have been divided into three major 
categories based on the parasite life stage; pre-erythrocycic, blood stage, and transmission-
blocking, each of which have distinct immunological requirements for efficacy (Figure 10).  
Much effort has focused on the development of pre-erythrocitic/liver stage candidates, which 
aim to block infection by targeting antigens expressed early in the life cycle. The most 
commonly studied antigen in this category is circumsporozoite protein (CSP), the predominant 
surface antigen on sporozoites which contains immunodominant B cell and T cell epitopes 
(Crompton et al. 2010).  The RTS,S vaccine candidate, based on the pre-erythrocytic 
Plasmodium falciparum CSP protein, has shown around 40% efficacy immediately after 
vaccination for the four-dose regimen, but protection wanes over time.  RTS,S efficacy has 
been correlated with anti-CSP Ab titers (Kazmin et al. 2017).  However, an alternative pre-
erythrocytic vaccine that has shown efficacy in controlled human infection models is based on 
whole irradiated sporozoites, which appears to function through hepatic CD8 T cell responses 
(Epstein et al. 2011; Ishizuka et al. 2016).  Clinical symptoms of malaria are only seen after 
the parasite enters the bloodstream, and naturally acquired immunity typically develops 
against the blood stage of the parasite.  Therefore, vaccines targeting the blood stage aim to 
mimic natural immunity, and instead of providing sterilizing protection they can reduce 
parasitemia and clinical symptoms, largely through antibodies and CD4 T cells (Crompton et 
al. 2010).   
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Finally, transmission-blocking vaccines (TBVs) are designed to target the parasite within the 
mosquito vector to interrupt the life cycle and thereby lead to malaria elimination (Hoffman et 
al. 2015). This is a unique approach that targets antigens in the mosquito midgut through 
vaccine-elicited antibodies taken up during the blood meal. This method takes advantage of 
the conserved antigens expressed within the mosquito midgut, which have not undergone 
centuries of immune pressure within the human host.  Additionally, this is one of the few stages 
where the parasite exists extracellularly and in relatively small numbers, making it a prime 
target for antibodies.  This would result in blockage of parasite replication in the mosquitos 
and thus limit the parasite burden overall. The caveat is that the vaccinated individuals 
themselves would not be protected, but with enough vaccinated individuals in a population 
malaria transmission could ultimately be eradicated. In my thesis we have evaluated a TBV 
targeting the most clinically advanced antigen, P. falciparum protein Pfs25.  Although this 
antigen has progressed to clinical trials (Talaat et al. 2016; Wu et al. 2008), it has failed to 
induce robust and sustained Ab titers necessary for clinical implementation. While there are 
many possible targets for malaria vaccination, it is clear that all will require an in depth 
understanding of vaccine elicited immunity to guide rational vaccine design. 
 
Figure 10: Different stages of plasmodium falciparum life cycle targeted by vaccination and proposed 
immunological mechanisms for protection. 
There have been significant challenges for the field of vaccinology posed by both vaccines 
requiring CD8 T cell responses and the high levels of sustained Ab titers required for malaria 
vaccination.  In my thesis, we have aimed to advance the understanding vaccine-elicited 
immunity to better inform rational vaccine design to help overcome these obstacles.  
Information of this kind can be used to tailor the appropriate vaccine adjuvant, formulation, 
and even route of delivery, to elicit the necessary adaptive immune responses.   
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4.2 ADJUVANTS 
4.2.1 History of adjuvants 
The increased understanding of basic immunological processes, as described above, has 
spurred the design of many novel vaccine adjuvants in recent years.  Vaccine adjuvants are 
components added to non-live vaccine formulation in order to improve the immunogenicity 
and direct the resulting adaptive response.  While adjuvants have been used for more than 90 
years (Pasquale et al. 2015), they were largely developed empirically in the past. The most 
commonly used adjuvant, aluminum salts (alum), was the only licensed adjuvant in humans 
for 70 years, although the mechanism of action is still incompletely understood.  Alum primarily 
increases Ab responses, and so far, no alum adjuvanted vaccine has been able to induce 
protective cellular responses.  In general, most vaccines protect by eliciting protective Ab 
responses (Plotkin 2010), and there are still no fully effective vaccines for a variety of diseases 
that will likely require TH1/CD8 T cell immunity, in addition to Ab responses.    
Traditionally, adjuvants were primarily used to increase the magnitude of responses, but now 
it is becoming increasingly important to guide the specific type of adaptive response needed.  
In addition, as vaccines move towards using more purified antigens to increase safety, they 
become less efficacious and need stronger adjuvants to increase immunogenicity. Most of the 
purified antigens in use now typically lack PAMPS and therefore are incapable of initiating 
immune responses on their own (Coffman et al. 2010).  Thus, many next generation adjuvants 
aim to exploit the power of the innate immune system to provide both an increased magnitude 
and qualitative alteration of the immune response. In fact, it seems almost all adjuvants 
enhance adaptive immunity by engaging the innate immune system, not the adaptive 
lymphocytes themselves (Coffman et al. 2010).  
4.2.2 TLR-based adjuvants 
Vaccine adjuvants have long been considered to 
function through two primary modalities, 
immunostimulatory agents or passive depots or 
vehicles.  There is now increased evidence that 
even adjuvants long thought of as passive 
depots (e.g. alum) also stimulate innate 
immunity (Marrack et al. 2009; Mosca et al. 
2008).  In my thesis I focused on 
immunostimulatory compounds, including 
targeting PRRs and DC activating pathways, 
such as CD40.  One of the most common ways 
to target PRRs is through natural or synthetic 
ligands to TLRs, of which a variety have been 
targeted.  We have tested adjuvants targeting TLR3, TLR4, TLR7/8, and TLR9, all of which 
are in advanced stages of clinical or pre-clinical testing.  These TLRs are located either on the 
cell surface or in endosomes (Figure 11), and are restricted to expression on distinct cell types 
(Figure 12) (Thompson & Loré 2017).  Therefore, TLRs offer the ability to specifically target 
different cell types and compartments of the cell.  
Figure 11: TLR distribution in the cells and 
examples of adjuvants targeting these TLRs. 
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Figure 12: TLR distribution across APC subsets in human, rhesus macaque, and mouse. 
Synthetic analogs of the TLR3 agonist, double stranded RNA, have been developed (PolyIC) 
and are able to potently activate innate immunity when used as an adjuvant (Longhi et al. 
2009; Stahl-Hennig et al. 2009; Trumpfheller et al. 2008).  PolyIC can act through two distinct 
pathways, activating TLR3 in endosomes or RIG-I and MDA5 in the cytosol.  PolyIC activation 
of TLR3 in DCs induces IL-12 and type I IFN production as well as improving MHC-II 
expression and cross presentation (Grewal & Flavell 1998; Krug et al. 2001; Schulz et al. 
2000).  MDA5 activation occurs primarily in non-hematopoeitc cells (stromal cells) and induces 
strong production of type I IFNs, which may further enhance DC maturation and be critical for 
optimizing the generation of TH1 and CD8 T cell immunity (Longhi et al. 2009).  PolyIC and its 
derivatives (i.e. Poly IC:LC) have been tested in several clinical trials (Hartman et al. 2014; Kyi 
et al. 2018; Mehrotra et al. 2017; Okada et al. 2015; Pollack et al. 2014; Tsuji et al. 2013).  
To date, the only licensed TLR-based adjuvants target TLR4.  The natural ligand to TLR4 is 
bacterial lipopolysaccharide (LPS), but adjuvants primarily use a detoxified derivative, 
monophosphoryl lipid A (MPL), or a synthetic analog, glucopyranosyl lipid adjuvant (GLA).  
The hepatitis B virus (HBV) and human papilloma virus (HPV) vaccines are both adjuvanted 
with AS04, which combines alum and MPL (Garçon & Mechelen 2011).  These two vaccines 
were licensed in 2005 and 2007, respectively (Garçon & Pasquale 2016).  However, it has 
long been known that LPS was a potent stimulator of the immune system and could effectively 
function as an adjuvant, (Johnson & Jackson 2014), but the highly activating profile has been 
associated with a myriad of side effects (Beutler & Rietschel 2003). Since vaccine adjuvants 
are typically delivered to healthy individuals, it is critical to have a strong safety profile.   New 
technology and formulations have been able to strike a balance between immune potency and 
unintended side effects.  TLR4 can signal either via MyD88 or TRIF pathways, leading to 
proinflammatory cytokines or type I interferons, respectively (Lu et al. 2008).  Additionally, 
targeting TLR4 on murine B cells leads to B cell proliferation and Ab secretion (Gururajan et 
al. 2007).  However, human and non-human primates (NHPs) express low levels or non-
functional levels of TLR4 and are therefore not responsive to stimulation (Bekeredjian-Ding et 
al. 2005).  The success of TLR4-targeting vaccines in humans may consequently rely on 
innate activation of myeloid cells to provide proinflammatory cytokines.  
TLR7 and 8 are expressed in the endosome and recognize single stranded RNA, as found in 
viruses such as HIV and influenza.  Small molecule agonists have been discovered to target 
TLR7 and 8, with the most heavily studied being synthetic imidazoquinolines, such as 
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imiquimod and resiquimod (R848) (Adams et al. 2012; Dowling 2018; Maldonado et al. 2015; 
Sabado et al. 2015). Similar to the natural ligand, these synthetic small molecules can activate 
TLR7 and/or 8 within the endosome to initiate the activation of MyD88 and depending on the 
cell type will then drive a largely IRF7 dependent pathway initiating type I IFN genes or the 
NF-kB pathway to induce proinflammatory cytokines.  While PDCs are prone to produce high 
levels of IFNa in response to TLR7 stimulation, monocytes and myeloid DCs primarily produce 
proinflammatory cytokines such as IL12 and are capable of skewing a TH1 response.  Despite 
the strong promise of TLR7/8 ligands such as R848 for vaccine adjuvants, they have to date 
failed to reach widespread clinical use due to the associated side effects.  This is largely due 
to the small molecule size, which allows the adjuvant to diffuse away from the injection site 
and lead to systemic activation and reactogenicity.  However, recent efforts at vaccine 
formulation have demonstrated that these effects can be overcome through multiple methods 
of formulation, such as encapsulation into nanoparticles (Ilyinskii et al. 2014; Kasturi et al. 
2011, 2017), conjugation to polymer backbones (Lynn et al. 2015), and absorption to alum 
(Liang et al. 2017; Wu et al. 2014).  These developments have ushered in a new generation 
of adjuvants, which can potently activate the immune system while mitigating the systemic 
effects of unformulated TLR7/8 agonists.   
Finally, TLR9 agonists based on CpG have long been investigated for their potential as 
vaccine adjuvants.  CpG-based adjuvants have been evaluated in a variety of phase I and II 
clinical tests for infectious diseases and cancer therapy (Bode et al. 2014).  TLR9 recognizes 
bacterial DNA, which is rich in unmethylated CpG motifs, whereas eukaryotic DNA typically 
lacks these motifs.  Multiple classes of synthetic analogs of CpG have been developed and 
while there are similarities between the classes, each preferentially activates TLR9 in different 
species or cell types. TLR9 is predominantly expressed by PDCs and B cells in humans 
(Hemmi et al. 2000; Takeshita et al. 2001).  CpG class A (also known as D) principally target 
PDCs to produce IFNa through MyD88/IF-7 signaling, but have limited effect on B cells. IFNa 
can skew TH1 responses and may therefore be useful for inducing CD8 T cell responses.  
Class B (or K) are highly efficient at stimulating B cell proliferation and Ab secretion.  Class C 
have similarities with both Class A and B and can stimulate B cells to produce IL-6 and PDCs 
to produce IFNa. Therefore, the specific class of CpG can be tailored to the needed response 
for a given vaccine.   
4.2.3 CD40 targeting adjuvants 
An alternative innate pathway particularly important in generating T cell responses is the 
CD40/CD40L pathway as described previously.  Targeting CD40 as a vaccine adjuvant has 
been tested in a variety of preclinical and clinical models. Mouse models have shown that DCs 
can receive CD40 stimulation independent of T cell help by administering either agonistic anti-
CD40 Abs, soluble CD40L or an adenovirus vector expressing CD40L, all of which have 
shown enhanced CD8 T cell responses (Davis et al. 2006; Gladue et al. 2011; Hanyu et al. 
2008).  Preclinical data also suggests that combining a TLR-ligand with agonistic anti-CD40 
Abs induces a several fold increase of CD8 T cell responses compared to either agonist alone 
(Ahonen et al. 2004; McWilliams et al. 2010; Sanchez et al. 2007).To further this notion, a 
mouse cancer model showed that delivering synthetic peptides together with anti-CD40 Ab 
and the TLR3 ligand, polyIC, (TriVax) induced high levels of antigen-specific T cell responses 
and tumor reduction (Assudani et al. 2008).  Targeting CD40 may therefore be particularly 
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potent as a vaccine adjuvant with the synergy provided by another innate pathway. Recently, 
there is also increased interest in combining CD40 targeting with immune check point 
blockades, which is currently being tested in clinical trials (Vonderheide 2018).   
Of all methods tested for targeting CD40, monoclonal Abs (mAbs) have achieved the most 
clinical attention (Figure 13).  To date, all clinical trials involve testing the various CD40 Abs 
for their potency in cancer immune therapy.  The range of CD40 mAbs have diverse activities, 
varying from agonism to antagonism, and further investigation is needed to fully explain the 
heterogeneity (Vonderheide & Glennie 2013). There are currently three major agonistic clones 
undergoing clinical investigation (Table 1) and several antagonistic clones.  However, it has 
been difficult to directly compare data generated in mouse models to Abs in clinical use, as 
they use rodent and human isotypes, respectively.  While mouse models showed that the Ab 
istoype and interaction with FcR may play a large role in determining the profile of CD40 Abs 
(Li & Ravetch 2011), recent reports evaluating the human IgG2 clone CP-870,893 (now known 
as RO70097890/Selicrelumab) instead propose that epitope specificity plays a dominant role 
(Richman & Vonderheide 2014).  This clone is the most widely studied in clinical trials and 
also the most agonistic. Interestingly, this clone was chosen in part because the IgG2 isotype 
is known for having relatively low FcγR interaction.  In vitro tests showed that the Ab 
maintained activity in the absence of cross-linking, unlike the mouse counterpart, and could 
still function with an inactive or removed Fc portion.  Since it was found that clones commonly 
used in mouse studies bind to the CD40L binding site, whereas the human clone does not, it 
has been proposed that the differences lie in epitope specificity.  However, this debate is far 
from over, as studies evaluating the human clone CP-870,893 in a mouse model expressing 
human CD40 and FcR again showed that in vivo activity was dependent on Fc signaling 
(Dahan et al. 2016).  Therefore, it seems that even Abs designed to have low Fc engagement 
could be further optimized through Fc engineering. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Proposed function of monoclonal anti-CD40 Ab targeting of APCs for enhanced antigen presentation. 
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Ab Name Ab 
Isotype 
Company/ 
Institution 
Clinical Trials 
Status 
Conditions NCT Numbers 
ADC-1013 
(JNJ-
64457107) 
Fully 
human 
IgG1 
Alligator 
Biosciences 
1 Completed; 
1 Recruiting 
Neoplasms, Solid 
Tumors 
NCT02379741, 
NCT02829099 
Chi Lob 7/4 Chimeric 
IgG1 
Cancer 
Research 
UK 
1 Completed Cancer, Neoplasms, 
Lymphoma, Non-
Hodgkin, B-Cell 
NCT01561911 
CP 870,893 Fully 
human 
IgG2 
Pfizer 1 Active, not 
recruiting;  
6 Completed 
Melanoma, 
Advanced Solid 
Tumors, Pancreatic 
Neoplasm, 
Adenocarcinoma 
Pancreas 
NCT01103635, 
NCT02225002, 
NCT01008527, 
NCT00711191, 
NCT02157831, 
NCT00607048, 
NCT01456585 
Selicrelumab 
(RO70097890) 
Fully 
human 
IgG2 
Roche 4 Recruiting Pancreatic Cancer, 
Advanced/Metastatic 
Solid Tumors, Solid 
Tumors, Pancreatic 
Adenocarcionma 
NCT02588443, 
NCT02665416, 
NCT02304393, 
NCT03193190 
Table 1: Overview of agonistic CD40 mAb that have been tested in clinical trials. 
While immunotherapies targeting CD40 have gained significant attention, there have also 
been safety concerns for such a highly immunostimulatory formulation.  There is a potential 
for a myriad of side effects, including inducing cytokine release syndrome, autoimmune 
reactions, and cell death or tolerance due to overstimulation. However, it is important to note 
that none of these reactions have been seen in a significant way in the clinic (Vonderheide 
2013).  The strongest agonist, CP-870,893 (now Selicrelumab), has only led to mild cytokine 
release syndrome, which was transient and easily managed.  There have also been no 
reported cases of autoimmunity following administration.  However, it is still possible that local 
activation of DCs may overcome these potential hurdles.  It has been shown that delivering 
the CD40 Ab SQ adjacent to the tumor restricts distribution to the tumor draining lymph node 
and lowers toxicity, while still maintaining the same effect (Fransen et al. 2011).  Furthering 
this notion, CD40 targeting mAbs may benefit from alternative routes of administration, which 
allow for more localized and direct targeting of DCs.  
4.3 THE ROLE OF VACCINE FORMULATION 
Much work in recent years has focused on developing novel vaccine adjuvants, as described 
above.  However, it has become increasingly clear that the simple combination of a correct 
antigen and adjuvant is not sufficient to generate protective responses (Moyer et al. 2016).  
Instead, it is necessary to properly formulate these sub-unit vaccines to achieve the proper 
biodistribution, pharmacodynamics, and ideally to mimic the molecular structure and 
appearance of the natural pathogen.  A promising avenue to achieve all of these requirements 
is through nanoparticle formulation.  Nanoparticulate formulation can improve antigen 
targeting to the lymph node, uptake and presentation to T cells, antigen retention within the 
lymph node, and B cell activation.  Nanoparticles can be designed in a range of sizes, with 
multiple materials, and with different antigen densities and display.  Therefore, they offer a 
prime technology to specifically enhance cellular and humoral responses. 
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Following immunization, antigen must be trafficked to lymph nodes to interact with B cells and 
T cells and initiate an immune response.  Antigen can either traffic freely via lymphatic 
drainage or be transported by APCs.  Typically, vaccines are delivered to the muscle, which 
has limited lymph drainage and therefore a large proportion of the antigen is transported via 
APCs (O’Hagan et al. 2012).  In contrast, delivering vaccines via the SQ or intradermal route 
allows for more efficient lymphatic drainage, and higher levels of free antigen reaching the 
lymph node.  However, the size of the particle is critical for efficient lymphatic drainage (Figure 
14).  The blood drains significantly higher amounts of fluid from the tissue than lymph, but is 
limited to small proteins due the tight junctions of the endothelial cells.  It has been 
demonstrated that there is a direct relationship between particle size and lymphatic drainage, 
where particles above approximately 45kD traffic almost exclusively by the lymphatics (Miller 
et al. 2011; Supersaxo et al. 1990).  This may explain the poor immunogenicity of peptide 
antigens and high cytotoxic events associated with low molecular weight adjuvants, due to 
increased systemic distribution via the blood stream.  Therefore, formulating both antigens 
and adjuvants into nanoparticle structures, where the size and shape can be designed to avoid 
systemic exposure, offers possibilities to increase immunogenicity of relatively non-
immunogenic antigens and increase the safety profile of highly activating adjuvants.  The size 
of particle also plays a role in retention in the LN.  Smaller particles (approximately 30nm) may 
flow through the lymph node and 
reenter circulation via the thoracic 
duct, reaching concentrations similar 
to intravenous administration (Kourtis 
et al. 2013). Therefore, synthetic 
nanoparticles, liposomes, and virus-
like particles (VLPs) all offer 
opportunities to enhance vaccine 
drainage and retention in the lymph 
node based on size alone (Fifis et al. 
2004; Kanekiyo et al. 2013; Link et al. 
2012; Moon et al. 2011; Reddy et al. 
2007).  Nanoparticle size can also 
increase uptake by APCs and thereby 
more efficiently promote T cell 
responses (Manolova et al. 2008; 
Reddy et al. 2006).  
Apart from increased lymphatic drainage, nanoparticles can provide a similar structure to 
pathogens.  Bacteria and viruses often have a dense array of antigens expressed on the 
surface to facilitate infection.  Therefore, increased antigen valency can better mimic natural 
structures, and has been shown to be superior in BCR cross-linking and activation of B cells, 
as well as antigen uptake by B cells and presentation to cognate T cells (Jegerlehner et al. 
2002; Kim et al. 2006; Temchura et al. 2014).  Prime examples of these repetitive structures 
are VLPs, which are utilized by HPV and HBV vaccines, and the malaria vaccine RTS,S.  The 
highly successful nature of these new vaccines indicates this could be an approach to improve 
formulations where increased potency is required.   
Figure 14: Size-dependent transport of antigen via blood and 
lymphatics. 
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4.4 ROUTE OF DELIVERY 
Another approach to influence vaccine-elicited responses is by using alternative routes of 
administration.  The skin has gathered a lot of interest in the past decade after being 
recognized as an ideal anatomical target for vaccination due to its dense network of different 
subsets of DCs including epidermal LCs and populations of dermal DCs (dDCs), as well as 
increased lymphatic drainage as discussed above. DCs in the skin can easily be targeted and 
pick up vaccine antigen to be transported via lymphatics to the local draining lymph node 
(Teunissen et al. 2012). A more localized and contained response could lead to a better safety 
profile, dose-sparing, and an alternative homing pattern of vaccine-generated T cells 
(Teunissen et al. 2012).  Understanding if there is differential T cell stimulation provided by 
phenotypically and functionally specialized DC subsets, with distinct plasticity in responding to 
extrinsic signals, represent essential information in the development of vaccines. The interest 
in targeting skin DCs for vaccination has motivated studies to compare skin vaccination to 
classical IM vaccination. Delivering the seasonal influenza vaccine in the skin compared to 
conventional IM injection resulted increased immune responses and dose sparing (Roukens 
et al. 2012).  In fact, many of the recent clinical trials evaluating peptide-based cancer vaccines 
have been administered intradermally or SQ (Noguchi et al. 2013; Reuschenbach et al. 2016; 
Slingluff et al. 2013; Takahashi et al. 2013).  
Additionally, delivery of vaccines via mucosal routes has been shown to be an effective 
method for induction of T cells that can home back to the site of immunization and site-specific 
TRM, as well as mucosal IgA.  Mucosal surfaces act as a barrier to the external world, and are 
therefore often a primary site of infection for a variety of diseases.  Vaccine-elicited responses 
at the barriers may then be able to provide a front-line defense.  There are already several 
clinically approved vaccines that are delivered via mucosal routes, most commonly via the oral 
route, including vaccines against polio, cholera, rotavirus, and typhoid (Shakya et al. 2016).  
Intranasal delivery offers easy access to the lung mucosa, and has been shown to induce 
protective TRM following immunization for influenza, RSV, and immunotherapies for cancer 
(Kinnear et al. 2018; Nizard et al. 2015; Sandoval et al. 2013; Slütter et al. 2013, 2017; Zens 
et al. 2017).  It is known that DCs from different mucosal tissues such as lung or gut can imprint 
T cell homing back to the site of infection (Iwata et al. 2004; Johansson-Lindbom et al. 2005; 
Mikhak et al. 2013; Mora et al. 2003, 2005).  Targeting of local APCs via mucosal delivery may 
therefore explain the increased induction of TRM.  However, many of the barriers established 
to prevent invasion from foreign pathogens can also act as a barrier to vaccine uptake, thus 
special attention needs to be taken to vaccine formulation for successful mucosal delivery.  
4.5 MODELS FOR VACCINATION 
To date, most preclinical evaluations and mechanistic studies for vaccine formulations are 
performed in mice.  However, these studies are not always translatable to humans as there 
are significant differences between the responses seen in mice and humans, likely due to 
differences in cellular expression patterns of PRRs.  In addition, there are often very different 
conditions used in mouse studies when compared to clinical practice.  Murine studies 
frequently use intraperitoneal or intravenous delivery routes, as opposed to the commonly 
used SQ or IM routes in humans.  These different routes of administration can lead to different 
antigen presentation by specific DC subsets, as discussed above.  In contrast, NHPs offer 
several distinct advantages over the traditional mouse model.  NHPs have more similar DC 
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subsets and PRR expression to humans and more invasive sampling allow for more complete 
mechanistic studies and a bridge between mice and humans.  Additionally, human reagents 
can be used in NHPs, allowing for more readily translatable data.  In vitro studies using human 
peripheral blood cells can generate much data, but these in vitro studies have their limitations.  
In vitro cultures typically will not include cells that are not in circulation, which can also 
contribute to the immune response by adding a bystander effect.  Further, these studies 
cannot easily replicate differences in anatomical distributions or persistence at an injection 
site.  Therefore, it is important to have a clinically relevant model where you can follow up on 
in vitro findings and better evaluate vaccine formulations.  
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5 MATERIALS AND METHODS 
5.1 SAMPLE MATERIAL 
Approval for animal studies was granted by the Animal Care and Use Committees of the 
Vaccine Research Center, National Institutes of Health (NIH) (I-II) or the Stockholm Ethical 
Committee on Animal Experiments organized under the Swedish Board of Agriculture (III). 
Indian rhesus macaques were housed at Bioqual, USA (I-II), or Astrid Fagraeus Laboratory at 
Karolinska Institutet (III) and handled according to the standards of the Association for 
Assessment and Accreditation of Laboratory Animal Care. The work on human sample 
material was performed at both the NIH, USA and the Karolinska Institutet, Sweden and 
approved by the relevant Institutional Review Board (I-II).  Signed informed consent was 
obtained in accordance with the Declaration of Helsinki.  
5.2 IMMUNIZATIONS  
In papers I-II, rhesus macaques were immunized with 1.5mg/kg anti-CD40Ab (clone 341G2 
IgG2), 1mg poly IC:LC (Oncovir), and 1mg/kg HIV-1 Env peptides (Biomatik) either via the IV 
(I-II) or SQ (II) route of administration. The CD40Ab was tracked in vivo by conjugating it to 
Alexa680 according to standard protocols (Molecular Probes) prior to immunization (I-II).  
In paper III rhesus macaques were immunized with 50µg of Pfs25 protein either formulated in 
a synthetic vaccine particle (SVP[Pfs25]) or as a conjugate (Pfs25-EPA). Group 1-3 received 
SVP[Pfs25] with 500µg CpG (Gr 1), 150µg R848 (Gr 2) or GLA-LSQ containing 12.5µg GLA 
and 25ug QS21.  Immunizations were delivered in a volume of 1ml SQ.  Rhesus macaques 
in group 4 were immunized IM with Pfs25-EPA containing 50µg of Pfs25 mixed with GLA-LSQ 
containing 25ug GLA and 50ug QS21 in a volume of 0.5ml. 
5.3 RHESUS TISSUE AND BLOOD SAMPLING 
Peripheral blood mononuclear cells (PBMCs) were purified by a density-gradient with Ficoll-
Paque (GE Healthcare) according to standard protocols (I-III). For biodistribution studies (I-II), 
tissues were collected after termination and processed to a single cell suspension by manually 
disrupting the tissue and filtering through a 70um cell strainer. Liver samples were further 
purified with Ficoll-Paque. Lung and gut tissues were digested with collagenase treatment and 
mechanically disrupted using the gentleMACS Dissociator (Miltenyi). 
5.4 CYTOKINE SECRETION ASSAY 
Cytokine secretion was evaluated in plasma of rhesus macaques (I-III) or cell culture 
supernatants (II) using multiplex technology or commercially available ELISA kits according to 
manufactures protocols.  
5.5 ANTIGEN RECALL ASSAY 
For assessment of antigen-specific cytokine production, PBMCs or single cell suspensions 
from tissues were restimulated in vitro. 1.5x106 cells were cultured in 200ul of complete 
medium per stimulation in a 96 well plate. Samples were stimulated as previously described 
with 2ug/ml of 9-13mer overlapping HIV-1 Env peptides (matched to immunization, I-II) or 
overlapping peptides (15mers overlapping by 11 amino acids) spanning the entire Pfs25 
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protein (III) in the presence of 10μg/ml brefeldin A (Sigma) overnight.  Samples were stained 
the following morning to evaluate cytokine production.  
5.6 MULTIPARAMETER FLOW CYTOMETRY 
Samples were first stained with LIVE/DEAD Fixable Dead Cell kit (Invitrogen), then blocked 
with FcR-blocking reagent (Miltenyi). Samples were then surfaced stained with a panel of 
fluorescently labeled antibodies.  For intracellular staining, cells were then fixed and 
permeabilized using Cytofix/Cytoperm solution (BD Biosciences) and followed by a panel of 
fluorescently labeled antibodies for intracellular staining.  Samples were resuspended in 1% 
paraformaldehyde prior to acquisition on a Fortessa flow cytometer or modified Fortessa X-50 
(BD Biosciences).  
5.7 ISOLATION OF HUMAN APCS 
Skin samples were obtained from patients undergoing breast reconstruction surgery (II) 
(Karolinska University Hospital, Stockholm, Sweden). To isolate skin APCs, skin pieces were 
cut using a skin graft mesher (Zimmer) then incubated in 2U/ml Dispase (Life Technologies) 
overnight at 4°C. After separating the epidermis from the dermis, both fractions were incubated 
in 26 WU/ml Liberase (Roche) and 20 U/ml DNase I (Roche) in a gently shaking incubator 
(80rmp) at 37°C for 1h.  Cells were then filtered prior to use.   
APCs were enriched in blood by using RosetteSep monocyte enrichment kit (StemCell 
Technologies) according to manufacturer’s protocols (II).  For cell sorting experiments, cells 
were further purified using positive selection with CD14 microbeads (Miltenyi) and isolated 
using an autoMACs (II) (Miltenyi). 
5.8 B CELL ELISPOT 
A B cell ELISpot was used to determine the frequency of antigen-specific B cell subsets (III).  
Briefly, ELISpot plates were coated with Pfs25 protein, PBMCs or bone marrow was added to 
wells directly for enumeration of plasmablasts and plasma cells, or after a four-day stimulation 
to recall memory B cells.  Cells were then cultured overnight at 37°C followed by sequential 
incubation with biotinylated anti-human IgG (Jackson ImmunoResearch Laboratories), 
strepatividin-conjugated alkaline phosphatase (Mabtech) and developed using BCIP/NBT 
substrate (Mabtech).  Non-specific spots were subtracted from antigen-specific wells.   
5.9 MICROARRAY AND DATA ANALYSIS 
Following RNA extraction and microarray, data was filtered to only include genes that were 
detected in all samples of at least one group and probes without associated GeneID were 
excluded.  Microarray data has been submitted to National Center for Biotechnology 
Information GEO (accession no. GSE102909). Normalized data was analyzed to identify 
statistically significant genes using a paired two-tailed Students t-test. Probes were selected 
for further analysis if fold change > 2 and a raw p-value < 0.01. For functional pathway 
analysis, all genes were ranked by paired average fold change with respect to baseline for 
each vaccination group. Pre-ranked GSEA was performed with 1000 permutations using the 
Java interface (Broad Institute, software.broadinstitute.org/gsea/index/jsp). 
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6 RESULTS AND DISCUSSION 
6.1 CD40AB INDUCES LUNG-RESIDENT T CELL RESPONSES (PAPER I) 
As mentioned in the earlier sections, there is a growing need for vaccines that can elicit T cell-
based responses. However, there is a considerable gap in knowledge of how to bridge studies 
performed in mice, which often readily develop CD8 T cell responses, to those in humans, 
which have been exceedingly difficult to generate robust T cell responses.  In my studies, we 
therefore used the NHP model, whose immune system closely resembles that of humans. 
Data developed in NHPs should have the potential to be of much more physiological relevance 
and translational to humans. My first study focused on a vaccine adjuvant combining two 
components; Poly IC:LC to target TLR3 and an agonistic monoclonal CD40 Ab to target CD40.  
This adjuvant combination may ultimately be best suited for a therapeutic cancer vaccine with 
the aim to induce strong T cell responses. However, as a model antigen, we co-delivered the 
adjuvant with a pool of 6 HIV-1 envelope glycoprotein (Env) peptides, since they have been 
shown to be immunogenic in rhesus macaques. This model therefore allowed us to investigate 
each component of the adjuvant individually to determine the requirements for induction of 
CD8 T cell responses. The immunization was delivered IV to mimic the administration of many 
therapeutic cancer vaccine strategies. 
Similar to what has been reported in mice (Ahonen et al. 2004; McWilliams et al. 2010; 
Sanchez et al. 2007), we found that both anti-CD40Ab and Poly IC:LC were required to induce 
potent T cell responses.  Either adjuvant component alone only induced low levels of 
responses, but there was a synergistic effect when combining the two.  However, in contrast 
to the previous studies in mice, we found that regardless of immunization group, there was 
limited detection of T cell responses in the blood of rhesus macaques.  Instead, we found 
remarkably high frequencies (5-10%) of both CD4 and CD8 vaccine-specific T cells in 
bronchoalveolar lavage (BAL) of the animals (Figure 15A).  Interestingly, CD40Ab and Poly 
IC:LC were required in the prime immunization to induce CD8 responses in the BAL, as 
boosting with either anti-CD40Ab or Poly IC:LC could not reprogram T cells to become 
resident after priming with either of the components alone.  While we anticipated that this 
vaccine led to a general mucosal homing in the rhesus macaque model, we found that the 
responses were highly compartmentalized to the lung, and were found both in the lung tissue 
and the BAL (Figure 15B). Vaccine-specific T cells could not be detected at substantial levels 
in any other organ evaluated.  The majority of the antigen-specific T cells in the lung expressed 
the classical markers CD69 and CD103 expressed by TRM (Figure 15C).   
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Figure 15: Vaccine-specific CD8 T cell responses in rhesus macaques following immunization with anti-CD40Ab, 
Poly IC:LC and HIV-1 Env peptides. (A) CD8 responses over time in PBMCs (top) and BAL (bottom) differ 
depending on prime immunization. (B) CD8 T cell responses in different tissues after boost immunizations. (C) 
Vaccine-specific T cells in the lung expressed CD103 and CD69. 
To try to explain the compartmentalized T cell responses, we evaluated the biodistribution of 
the anti-CD40Ab, to determine if the adjuvant was also restricted to the lung. Since T cell 
priming by lung APCs has previously been shown to imprint lung homing (Mikhak et al. 2013), 
we reasoned that localized APC activation and T cell priming could instruct vaccine-specific T 
cells to home back to the lung.  We labeled the Ab with alexa-680 to track the Ab in vivo and 
determine tissue distribution and cell subset targeting (Figure 16). At 24 hours after IV 
administration, the Ab was widely 
disseminated and was not preferentially 
targeting the lung. Therefore, we concluded 
that this did not explain the restricted T cell 
responses in the lung and BAL. However, it 
is possible that had we evaluated the 
biodistribution at an earlier time point, the 
lung may have been the first target organ. 
We also observed that the Ab primarily 
bound to monocytes and neutrophils, despite 
their medium-low level of basal CD40 
expression. Both these cell populations have 
the ability to bind antibodies non-specifically 
via FcR, but can also upregulate CD40 upon 
immune activation.  The immunization 
induced rapid cytokine secretion and 
systemic immune cell mobilization and 
therefore likely upregulated CD40 
expression on these subsets.   
Figure 16: In vivo anti-CD40Ab binding and distribution 24 
hours after IV administration in rhesus macaques. 
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The unexpected finding of T cell responses restricted to the lung following this immunization 
regimen, indicated that this adjuvant combination may be particularly powerful for tumors in 
the lung and pathogens targeting the lung.  These findings also underscore the importance of 
evaluating immune responses in tissue in addition to peripheral blood, which is frequently the 
only sample available in human clinical trials.  Without the BAL sampling allowed for in the 
NHP model, it may have appeared that the combined activation of anti-CD40Ab and Poly 
IC:LC could not induce robust T cell responses outside of the murine model.  This realization 
initiated a general interest in mucosal biology and the ability to induce tissue homing and 
residence via vaccination.  These questions then resulted in the design of study II.   
6.2 IL-10 INDUCES TISSUE-RESIDENT MEMORY T CELLS (PAPER II) 
From our findings from Paper I, it was unclear whether the route of administration or inherent 
signaling due to the anti-CD40Ab/Poly IC:LC adjuvant led to the establishment of highly 
restricted TRM in the lungs of rhesus macaques.  Therefore, this project was initially developed 
largely to evaluate the requirements for tissue homing. To evaluate the possibility of route of 
administration in inducing T cell homing to the lung, we expanded on the rhesus macaque 
model and used two distinct routes of administration to compare the contributions of systemic 
vs local APCs in T cell priming and education.  By immunizing via the IV route as in paper I, 
or via the SQ route, we could evaluate the innate mechanisms leading to T cell homing to the 
lung and induction of a TRM phenotype.   
We again tracked the biodistribution of the anti-CD40Ab. Following SQ administration, we 
found that in contrast to IV administration, the Ab stayed highly localized in the skin and the 
skin draining lymph node, with macrophages and monocytes being the main APCs targeted.  
Immunizing the animals with the same adjuvant combination and Env peptides from paper I 
either via the IV or SQ route, we found that both regimens induced antigen-specific T cell 
homing to the lung (Figure 17A). This indicates that the lung homing ability of the T cells was 
not strictly a matter of route of administration, as both routes readily induced lung homing.  In 
fact, many vaccine formulations have induced T cell responses in the lung, regardless of 
immunization route (Darrah et al. 2014; Liu et al. 2010; Park et al. 2013). As the lung is highly 
vascularized and regularly exposed to environmental threats, this may be an common result 
of a multitude of APC:T cell interactions and is not limited to education by lung APCs.  
However, while there were no significant differences in terms of proportion of antigen-specific 
T cells between the groups, there was a striking difference in the proportion of CD103+ TRM 
within the antigen-specific population (Figure 17B).  IV immunization induced a significantly 
higher proportion of CD103+ TRM compared to SQ administration.  Together this data suggests 
that multiple routes of administration may induce lung homing, however local signals or early 
education of the T cell response could alter the ability to take up residence.  While the two 
routes of administration induced largely similar innate profile in terms of cell mobilization and 
cytokine secretion in the blood, there was a differential production of plasma IL-10 (Figure 
17C), which strongly correlated with the proportion of TRM (Figure 17D).  
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Figure 17: IV administration of anti-CD40Ab/Poly IC:LC/HIV-1 Env peptides induces lung-resident TRM that 
correlates with systemic IL-10 6 hours after immunization 
To be able to address mechanisms behind this finding and establish the connection between 
IL-10 and induction of TRM, I developed an in vitro system using primary human cells.  APCs 
purified from human skin or blood represented cells targeted by the SQ or IV routes of 
administration, respectively.  Following stimulation with anti-CD40Ab and Poly I:C, APCs 
isolated from all compartments showed the ability to increase naïve CD8 T cell proliferation, 
however, only the blood APCs could increase CD103 expression on the T cells following 
stimulation (Figure 18A).  Incidentally, blood APCs were also the only cells capable of 
producing high levels of IL-10 following stimulation, and the increase in CD103 expression 
could be inhibited with a neutralizing IL-10 Ab or increased with recombinant IL-10 (Figure 
18B).  
 
Figure 18: Blood APCs increase CD103 expression on naïve T cells following anti-CD40Ab/Poly IC stimulation in 
an IL-10-dependent manner. 
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However, we found that IL-10 did not directly signal through T cells to upregulate CD103, but 
instead conditioned monocytes to release TGFb and thereby induce a TRM phenotype.  We 
found that the release of TGFb from monocytes was increased if the cells were stimulated to 
produce IL-10. Blocking the IL-10 secretion with an anti-IL10 Ab also inhibited the release of 
TGFb (Figure 19A) and adding recombinant IL-10 
increased TGFb secretion (Figure 19B).  Active 
TGFb constitutively expressed by epithelial cells 
has earlier been demonstrated to have role in the 
induction of TRM, and has been implicated in the 
typical localization of TRM to epithelial 
compartments.  However, many details 
concerning the events leading to TRM generation 
and a possible role for TGFb prior to tissue entry 
or derived from activated immune cells within the 
tissue has not been well understood. 
To begin to understand where and when the influence of IL-10 and TGFb and interaction 
between monocytes and naïve T cells could occur, we established a timeline for the kinetics 
of CD103 upregulation.  Naïve T cells exposed to TGFb from the start of stimulation 
upregulated CD103 to the highest extent and could upregulate CD103 over several days. 
Further, naïve T cells primed in the presence of TGFb were more susceptible to subsequent 
TGFb signaling (Figure 20), indicating that priming in a lymph node in the presence of an IL-
10 activated monocytes could already destine T cells to be more responsive to the tissue 
microenvironment (Figure 21).  
 
Figure 20: Naïve T cells primed in the presence of TGFb are more susceptible to subsequent TGFb signaling. 
These findings indicate a possible mechanism for the recent success of recombinant IL-10 as 
an anti-tumor therapy and outline a new pathway to target with adjuvants for the induction of 
TRM.  Since multiple TLR ligands can induce IL-10, there are several possibilities for clinical 
implementation, including TLR-based adjuvants such as R848 or MPL and delivery of 
recombinant IL-10.  These strategies could be employed with so-called “prime and pull” 
methods to target specific tissues as needed for immunotherapies or preventative vaccines. 
Figure 19: IL-10 mediates TGFb release. 
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Figure 21: Summary of paper II. Activated monocytes produce IL-10 inducing the release of TGFb, which in turn 
upregulates CD103 on naïve T cells and makes cells more responsive to late TGFb signaling. 
6.3 TLR-BASED ADJUVANT VACCINES DIFFERENTIALLY IMPRINT VACCINE 
RESPONSES (PAPER III) 
In the third study in my thesis, the focus was again on how innate immune activation induced 
via different TLR-based adjuvants influences vaccine responses.  Here, we took a broader 
approach to evaluate multiple arms of the immune response to find correlates of vaccine 
immunity.  In a large preclinical vaccine study in rhesus macaques, I had the opportunity to 
side-by side compare how adjuvants targeting either TLR4, TLR7/8 or TLR9 influenced 
different aspects of innate immune activation and in turn polarized the humoral as well as 
cellular vaccine responses (Figure 22).  
 
Figure 22: Immunization groups in paper III and immunological parameters evaluated.  
An overall aim of the study was to evaluate the potency of a novel malaria vaccine that had 
been adjuvanted with the different TLR-agonists.  As mentioned in the introduction, TBVs 
represent a key strategy to eradicate malaria. A major challenge in the development of such 
vaccines has been that the strong Ab titers induced in mice did not translate into successful 
clinical vaccine trials (Talaat et al. 2016; Wu et al. 2008).  The leading antigen candidate, 
Pfs25, is poorly immunogenic on its own, although several studies in mice have demonstrated 
that multimerization of the protein greatly improves the vaccine responses. Despite this 
preclinical work, Pfs25-based vaccines have failed in clinical trials, indicating that more 
modern approaches to vaccine formulation are necessary. Further, mechanistic insights into 
how Pfs25 based immunity can be improved have been sorely lacking. We therefore utilized 
novel polymer-based nanoparticle vaccine formulations and multiple TLR-based adjuvants to 
overcome the poor immunogenicity of Pfs25. We tested these formulations in rhesus 
macaques and benchmarked against the most advanced formulation currently in clinical trials, 
Pfs25-EPA. Since transmission-blocking vaccines work via production of antibodies, the major 
focus was on the magnitude and longevity of the humoral response. While T cell responses 
and innate activation would have no direct protective effect, the study still offered an 
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opportunity to measure these parameters and correlate their levels with the magnitude and 
durability of the Ab response.  These findings are important not only for transmission-blocking 
vaccines, but are also applicable to various non-live platforms. We therefore used data 
generated from the wide array of immunological assays performed in this study to perform 
multiparameter correlation followed by hierarchical clustering (Figure 23).  This was a way to 
visualize how different arms of the immune response correlated with each other, and 
generated three primary clusters, that will be discussed in more detail below.   
 
By following the animals long-term, we could demonstrate that the nanoparticle formulation 
increased Ab titers and transmission reducing activity in mosquitos (Figure 24A-B), which 
correlated with increased induction of vaccine-specific B cell subsets including plasmablasts 
and memory B cells in the blood, and plasma cells in the bone marrow (Figure 24C-E). Since 
the nanoparticles were not specifically engineered to express Pfs25 on the outside in a way 
that was optimal for BCR cross linking, we suspect the increased Ab titers and B cell 
responses were instead driven by increased trafficking to the lymph node and uptake by APCs.  
Interestingly we also found that the adjuvants had differing efficacies in the prime vs boost 
setting.  While GLA-LSQ, the TLR4 ligand, showed a superior ability to prime responses, both 
CpG and R848 were better at boosting preexisting memory.  This may a result of the TLR 
expression on B cells.  Although B cells express TLR4 in mice, in humans and NHPS they 
express low levels or non-functional expression of TLR4.  In contrast, B cells in humans and 
NHPs express both TLR7/8 and TLR9, and could therefore be boosted directly with R848 and 
CpG.  
Figure 23: Parameters 
measured in the study at peak 
responses analyzed by 
multivariate nonparametric 
Spearman’s test and hierarchical 
clustering. The three primary 
clusters identified are marked.  
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Figure 24: Ab titers and B cell responses following immunization. (A) IgG Ab titers against Pfs25 over course of the 
study. (B) Transmission reducing activity as assessed by percent reduction of oocyst count in mosquito midgut with 
the addition of plasma from immunized animals. (C-E) Pfs25-specific B cell subsets as determined by ELISpot. 
Targeting distinct TLRs via the three different adjuvants induced differential innate immune 
profiles in terms of cytokine production and gene modulations (Figure 25A-B).  We found that 
adjuvants containing R848 and CpG induced a more robust innate activation that GLA-LSQ.  
The increased innate activation was notably seen in the skewing of cytokine production, where 
R848 in particular induced high levels of IFNα production and gene modulation (Figure 25A-
B).  The IFNα signature at the protein and gene level showed strong correlations with a 
substantially increased Ab half-life (Figure 25C), indicating that early innate education may not 
necessarily influence the magnitude of the Ab response, but could potentially alter the 
longevity of the response or even alter the imprinted lifespan of the LLPC. IFNα has been 
shown to directly stimulate B cell proliferation and promote survival through resistance to Fas-
mediated apoptosis.  Therefore, by promoting B cell survival, IFNα could possibly increase the 
ability to take up residence as a LLPC and increase Ab half-life.   
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Figure 25: Innate immune profile 24 hours after immunization correlates with Ab half-life.  (A) Plasma cytokine 
levels. (B) Innate gene modulation associated with inflammation/TLR signaling/chemokines and interferon/antiviral 
sensing as determined by Gene Set Enrichment Analysis using blood transcript modules. Shown is normalized 
enrichment score (NES). (C) Ab half-life after first and second boost, calculated using biphasic model. 
Previous vaccination efforts against Pfs25 had not been able to generate detectible Pfs25-
specific CD4 T cell responses, which could help explain the short-lived responses generated 
in clinical trials.  We found that the nanoparticle formulation tested here could overcome the 
poor immunogenicity of Pfs25 and generated the first reported Pfs25-specific CD4 T cell 
responses (Figure 26A). The T cells were phenotyped based on their ability to produce 
different cytokines following antigen restimulation in vitro.  The responding T cells 
predominantly produced IFNg, indicating a TH1 phenotype, or IL-21, indicating circulating TFH 
cells.  As discussed previously, TFH are a highly specialized CD4 T cell that provide B cell help.  
TFH found in the lymph node produce high levels of IL-21 and have been correlated with 
increased B cell activity and Ab levels following vaccination.  However, removing lymph nodes 
during an ongoing immune response may negatively influence ensuing responses, therefore 
ways to evaluate TFH and germinal center activity from peripheral samples have been 
established (Havenar-Daughton et al. 2016b, 2016a; Lindgren et al. 2017; Locci et al. 2013).  
Circulating TFH have been evaluated based on a variety of cell surface markers or IL-21 
production and have been shown to correlate with the level of TFH in the lymph node and share 
a common clonality, making them a feasible readout for TFH activity during vaccine trials.   Both 
TH subsets correlated with increased IgG Ab avidity (Figure 26B).  This is likely due to 
increased T cell help and activation within the germinal center, leading to higher affinity 
antibodies.  In line with this, we also saw higher levels of CXCL13 (Figure 26C), a chemokine 
involved in the organization of germinal center structures, which has been suggested as a 
plasma biomarker for germinal center activity, in groups receiving the nanoparticle formulation.  
Together, these data suggest that the PLGA-based nanoparticles increased Ab affinity and 
avidity by engaging T cell help.  This is possibly mediated by enhanced antigen uptake by 
APCs typically seen with nanoparticles.   
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Figure 26: Induction of TH subsets correlates with Ab avidity and germinal center activity. (A) Pfs25-specific TH cells 
induced by nanoparticle formulation. (B) Ab avidity as determined by modified urea ELISA. (C) Germinal center 
activity as measured by plasma CXCL13.  
Taking this type of broad approach to evaluate the generation of vaccine immunity allowed us 
to draw correlations between multiple arms of the immune system (Summarized in Figure 27).  
One of the more interesting findings was the potential relationship between IFNα produced 
early after immunization with the longevity of the Ab response.  As this is a major goal of 
vaccination efforts, this finding can help guide future adjuvant design and help the field to 
refine future vaccine formulations.  This may also help explain the highly successful nature of 
the yellow fever vaccine, which also generates a strongly IFNα skewed innate immune 
response.  Future efforts can use the correlations described here to delve deeper into the 
specific mechanisms of enhanced immune responses and to evaluate the feasibility of clinical 
implementation. 
 
Figure 27: Overview of findings from study III. Formulation of Pfs25 in nanoparticles increased circulating TH1 and 
TFH Pfs25-specific CD4 T cells compared to Pfs25-EPA.  Increased T cell responses correlated with increased titers 
and Ab avidity. TLR targeting adjuvants showed differing abilities to stimulate innate immune responses, R848 
induced robust IFNa production, which correlated with increase Ab half-life. Plasmablast phenotype was also 
differentially regulated by vaccine formulation with CXCR3+ and CD95- cells correlating with the highest Ab titers. 
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